Marie Wikström Lindholm
Chief Tech/Sci/R&D Officer at SILENCE THERAPEUTICS PLC
Profile
Marie Wikström Lindholm is currently the Director at Oligonucleotide Therapeutics Society, Inc. since 2022.
She is also the Chief Scientific Officer at Silence Therapeutics Plc since 2017.
Previously, she worked as an Assistant Professor at the University of Lund from 1999 to 2000.
Dr. Lindholm holds a doctorate degree from the University of Uppsala.
Marie Wikström Lindholm active positions
Companies | Position | Start |
---|---|---|
SILENCE THERAPEUTICS PLC | Chief Tech/Sci/R&D Officer | 30/11/2023 |
Oligonucleotide Therapeutics Society, Inc.
Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The private company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators. | Director/Board Member | 17/01/2022 |
Former positions of Marie Wikström Lindholm
Companies | Position | End |
---|---|---|
University of Lund | Corporate Officer/Principal | 31/12/1999 |
Training of Marie Wikström Lindholm
University of Uppsala | Doctorate Degree |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
SILENCE THERAPEUTICS PLC | Commercial Services |
Private companies | 1 |
---|---|
Oligonucleotide Therapeutics Society, Inc.
Oligonucleotide Therapeutics Society, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Beckman Research Institute of The City of Hope, Oligonucleotide Therapeutics Society, Inc. is a society that envisions a new era of oligonucleotide drugs that would change the landscape of therapeutic modalities. The private company is based in San Diego, CA. Over 100 treatments are in development for common conditions, including cancer and Alzheimer’s disease, as well as rare diseases. The society offers various awards to support the accomplishments of students, postdocs, and young investigators. | Commercial Services |
- Stock Market
- Insiders
- Marie Wikström Lindholm